FindTrial
Sign In

The observation on the effect of low-dose rosalastat combined with recombinant human erythropoietin on the improvement of moderate renal anemia in patients with chronic renal failure

The observation on the effect of low-dose rosalastat combined with recombinant human erythropoietin on the improvement of moderate renal anemia in patients with chronic renal failure

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300071419
Enrollment
Unknown
Registered
2023-05-15
Start date
2022-11-01
Completion date
Unknown
Last updated
2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal anemia

Interventions

Roxadustat group:No
ESA group:No
ESA + Roxadustat:No

Sponsors

Zhejiang Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1: adult patients(age=18 years) 2: chronic renal failure(eGFR<60ml/min.1.73m^2) 3: hemoglobin level range of 60-90g/L

Exclusion criteria

Exclusion criteria: 1: transferrin saturation (TSAT) 600 pg/ml 4: erum albumin concentration < 3.8 g/dL 5: evidence of acute or chronic infection, hematological disease, hemorrhage of digestive tract, sever heart failure (Class III/IV) or severe liver injury or active hepatitis 6: the level folate or vitamin B12 was below the lower limit of the reference range

Design outcomes

Primary

MeasureTime frame
mean rate of increase in Hb (g/dL/week) from baseline to the weeks 18-24;—

Secondary

MeasureTime frame
the change of average Hb level from baseline to weeks 18-24 without having received rescue therpy;hemoglobin response;red blood count;MCV;iron;Ferritin;Transferrin saturation;—

Countries

China

Contacts

Public ContactZhigui Zheng

Zhejiang Hospital

timdar317@163.com+86 150 5717 7126

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026